Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19

NCT06311435 · tracked via the Priya Life Science USA tracker

Sponsor

MaxWell Clinic, PLC

Phase

Not applicable

Started

2024-03-15

Last updated

2024-10-18

Condition(s) studied

Long COVID

Investigational drug(s) / intervention(s)

RNA Biomarker Blood Test

RNA Biomarker Blood Test: Blood will be collected into a PaxGene Blood tube for processing by sponsor

Study summary

The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the apparent health normal controls and other medical conditions that share the signs and symptoms of long COVID.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: * Mentally capable of understanding and completing informed consent for the study. * Precipitants with a lab verified diagnosis of SARS-CoV-2 or clinician note/record that an appropriate rapid test for SARS-CoV-2 was positive. * To qualify for long COVID group participants will need to have new, persistent symptoms related to SARS-CoV-2 infection. iv. No one under the age of 18. Exclusion Criteria: * Subject is unable to provide informed consent. * Primary Investigator or Sub-Investigator determines the participant's ongoing medical complaints that began after 1 November 2019 are not related to SARS-COV-2 but another disease process.

Primary outcome measure(s)

Develop algorithm to classify RNA sequences to identify long COVID — 30 days
The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the apparent health normal controls and other medical conditions that share the signs and symptoms of long COVID

Trial sites (3)

Facility	City	Region	Status
University of Iowa	Iowa City	Iowa	Not Yet Recruiting
The MaxWell Clinic	Brentwood	Tennessee	Recruiting
The MaxWell Clinic	Brentwood	Tennessee	Recruiting

Other trials for the same condition

A Study to Assess Anktiva in Patients With Long Covid-19. Recruiting

A Study to Examine Anktiva for the Treatment of COVID-19. Recruiting

NE3107 in Adults With Neurological Symptoms of Long COVID Active, not recruiting

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06311435 on ClinicalTrials.gov ↗ ← All trials in the USA